Searched for
MERCK LTD. SHARE PRICE
India's weight-loss drug boom raises questions over healthcare prioritiesIndia's market for cheaper anti-obesity drugs has surged tenfold. While demand is high, especially among those with diabetes, concerns abou...- Sun Pharma shares rally 9% in two days after $12-bn Organon deal. Here's what Morgan Stanley, other brokerages saySun Pharmaceutical Industries' shares surged nearly 9% after announcing the $11.75 billion acquisition of Organon & Co., a global leader in...
- Sun Pharma shares jump over 9% after firm announces $12 billion Organon acquisitionSun Pharmaceutical Industries' shares surged after announcing the $11.75 billion acquisition of US-based Organon & Co., a global leader in ...
- Sun Pharma looks to outshine rival bids with $13 billion Organon offerSun Pharmaceutical is making its biggest move yet with a $13 billion offer for Organon & Co. This ambitious bid aims to transform the India...
- Merck braces for Keytruda patent loss with $6.7 billion Terns betMerck is acquiring Terns Pharma for $6.7 billion to strengthen its cancer drug pipeline, aiming to reduce reliance on its blockbuster Keytr...
- Merck & Co to create a separate cancer unit as patent cliff loomsMerck & Co is restructuring by splitting its drug division into two separate businesses. The change is designed to spotlight its fastest-gr...
- Verona Pharma stock jumps 20% on $10B Merck deal—can FDA-approved Ohtuvayre reshape COPD care?Verona Pharma stock jumped 20% after Merck announced it will acquire the British biotech in a $10 billion deal. Merck will pay $107 per sha...
- Merck nears $10 bn deal for respiratory drugmaker Verona: ReportsMerck is close to buying Verona Pharma, a biotech firm specializing in lung diseases. The deal is valued at around $10 billion. Merck aims ...
- Merck has much to gain under P&G, stock soarsThe Street welcomed the move, with the stock climbing 19 per cent higher than the offer price of Rs 1,500.36 per share.
- Buy Merck, target Rs 1,610: Dharmesh ShahBuy Merck Ltd. at a price target of Rs 1610.0 and a stop loss at Rs 1465 from entry point.
- Merck receives demand notice from NPPA for overchargingIn a statement to the bourses the company said the government has issued the demand notice despite the fact that the company was neither a ...
- Merck to launch 13 innovator drugs hereUS-based Merck plans to launch 13 innovator drugs, including a blockbuster product in India, over the next two-three years.
- Merck buys Schering-Plough in $41.1b cash-&-stock dealUS-based Merck & Co is acquiring Schering-Plough for $41.1 billion in a cash-and-stock deal, to create a $47 billion drug major.
- Merck buys Schering-Plough for $41 bn to access new drugsUS-based Merck & Co on Monday said it is acquiring Schering Plough for $41.1 bn in a cash-and-stock deal to create a $42-bn drug major.
- Novartis ties up with USV to market Galvus in IndiaNovartis has tied up with leading healthcare company - USV - to market its anti-diabetic product Galvus.
- Analysts' picks: MerckLKP Shares has recommended a ‘buy’ rating on Merck on account of factors like the company is trading at book value and has a dividend yield...
- Terms didn’t fit stringent acquisition criteria: TevaTeva Pharmaceutical Industries said on Sunday it stopped pursuing the purchase of the generics unit of German drugs and chemicals group Mer...
- Merck to acquire biotech firm Serono for $13.3 bnGerman drugmaker Merck unveiled a surprise 16.6-bn-Swiss franc ($13.3 bn) deal to buy Swiss biotech firm Serono on Thursday, creating a new...
- Merck move is a threat to generic cosFirst, they sought extensions on patents to postpone market access to generic companies.
- Merck hikes Schering stake, threatens BayerGerman drugs and chemicals group Merck has raised its holding in rival Schering to just over 10%, threatening a planned takeover of Scherin...
Load More
